QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Condition: Solid Tumors or Multiple Myeloma
Sponsor: Nammi Therapeutics Inc
Full Title
Protocol QXL138AM-001: A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Study Treatment
QXL138AM is interferon alpha 2 (IFNα2) masked immunocytokine (MIC) fused to antibody targeting CD138
Eligibility/Info
- Solid tumors: Metastatic ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, or breast cancer that has continued to grow after standard systemic therapies.
- Multiple Myeloma: Multiple myeloma that has continued to grow after treatment with at least 3 lines of therapy that included an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulating agent.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.